Vincristine and Irinotecan in Children with Relapsed Hepatoblastoma: A Single-Institution Experience

Abstract

Purpose: This study was to determine the efficacy of vincristine and irinotecan in children with relapsed hepatoblastoma (HB). Methods: A total of 10 patients with relapsed HB were enrolled. Three patients were excluded. Patients received irinotecan 50 mg/m2/day, day 1–5 and vincristine 1.5 mg/m2/day, day 1, repeated every 3 weeks. The maximum cycles were eight. Reevaluation of tumor was performed every two cycles. The primary outcome was the rate of complete resection. Secondary outcomes were event-free survival (EFS) and overall survival (OS). Results: Of the seven patients assessable for response, one patient with normal AFP level showed a progressive disease and withdrew. He finally died 6 months later. Four had PR, all of them underwent a second surgery and achieved complete resection. Two patients had SD, one patient relapsed 6 months after orthotopic liver transplantation and died, the other one undergoing surgery had micro margin positive, he relapsed again but alive. The rate of complete resection was 71.4% (including orthotopic liver transplantation). The 2-year EFS and OS for the whole group were 57.1% (95% CI, 12.7% to 34.2%) and 71.4% (95% CI, 16.39% to 37.4%), respectively. Conclusions: The combination of irinotecan and vincristine has a significant antitumor activity and acceptable toxicity in children with relapsed HB.